Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Females must be non-pregnant, non-lactating, and either be post-menopausal for at least 12 months, have documentation of irreversible surgical sterilization, or confirm the use of one of the acceptable contraceptive methods~* Males must agree to avoid fathering a child and agree to use an appropriate method of contraception~* Chronic maintenance hemodialysis 3x a week for at least 3 months~* Chronic maintenance peritoneal dialysis for a minimum of 6 months~* Kt/V ≥ 1.2 at most recent measurement prior to screening~* Prescribed and taking at least 3 doses of phosphate binder per day~* Serum phosphorus levels should be between 4.0 and 8.0 mg/dL at screening~* Unchanged dose of vitamin D or calcimimetics for the last 4 weeks prior to screening~* For enrollment in the study after at least 2 weeks of wash-out, subjects must have serum phosphorus levels of at least 6.0 mg/dL but not more than 10.0 mg/dL and have had an increase of at least 1.5 mg/dL versus pre-wash out value after 2 or 3 weeks wash-out of phosphate binders~Exclusion Criteria:~* Severe hyperphosphatemia defined as serum phosphorus greater than 10.0 mg/dL on phosphate-binders at any time point during clinical routine monitoring for the 3 preceding months before screening visit~* Serum/plasma parathyroid hormone \>1200 pg/mL~* Clinical signs of hypovolemia at enrollment~* History of IBD or IBS-D~* Scheduled for living donor kidney transplant, change to peritoneal dialysis, home HD or plans to relocate to another center during the study period~* Positive serology with evidence of significant hepatic impairment or WBC elevation according to the Investigator~* Life expectancy \<6 months~* Previous exposure to tenapanor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tenapanor 10 mg, 20 mg, 30 mg BID (Type: EXPERIMENTAL): During the 26-week open label part, all enrolled subjects will receive 30 mg BID doses of tenapanor. Investigators may decrease or increase the dose in 10 mg increments to a minimum of 10 g BIDor a maximum of 30 mg BID
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Sevelamer Carbonate (Type: ACTIVE_COMPARATOR): Subjects randomized into the active control group, for safety analysis, will receive sevelamer carbonate, open label, for the entire 52-week study period. Sevelamer carbonate will be dosed based on package insert instructions (standard of care)

Based on this trial design, predict the completion outcome and termination type (if applicable).